Xin Lang Cai Jing·2025-09-09 03:39Core Viewpoint - 康龙化成's stock has experienced fluctuations, with a recent decline of 2.06%, while the company has shown a year-to-date increase of 25.22% in stock price [1] Group 1: Financial Performance - As of June 30, 康龙化成 reported a revenue of 64.41 billion yuan for the first half of 2025, reflecting a year-on-year growth of 14.93% [2] - The net profit attributable to shareholders for the same period was 7.01 billion yuan, which represents a decrease of 37.00% compared to the previous year [2] - Cumulative cash dividends since the company's A-share listing amount to 17.94 billion yuan, with 10.07 billion yuan distributed over the last three years [3] Group 2: Shareholder and Market Activity - As of June 30, 2025, 康龙化成 had 87,900 shareholders, an increase of 10.12% from the previous period [2] - The stock's trading activity showed a net outflow of 42.88 million yuan from main funds, with significant buying and selling activity recorded [1] - Major shareholders include 中欧医疗健康混合A and 香港中央结算有限公司, with notable changes in their holdings [3] Group 3: Business Operations - 康龙化成 specializes in drug research, development, and production services, with its revenue composition being 60.43% from laboratory services, 21.58% from CMC services, 14.58% from clinical research services, and 3.28% from large molecule and gene therapy services [1] - The company operates within the pharmaceutical and biotechnology sector, specifically in medical research outsourcing [1]